{"id":1009184,"date":"2026-10-12T08:04:48","date_gmt":"2026-10-12T12:04:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/"},"modified":"2026-10-12T08:04:48","modified_gmt":"2026-10-12T12:04:48","slug":"odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/","title":{"rendered":"Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026"},"content":{"rendered":"

\nTopline induction results expected in the second half of 2027
\n<\/h2>\n
\n

BOSTON, Oct. 12, 2026 (GLOBE NEWSWIRE) — Odyssey Therapeutics, Inc.<\/a> (Nasdaq: ODTX) (\u201cOdyssey\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that it will present the design of a randomized, double-blind Phase 2a trial evaluating OD-001 in combination with vedolizumab in patients with moderate-to-severe ulcerative colitis (UC) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, taking place October 9-14, in Nashville, Tennessee.<\/p>\n

The trial is designed to evaluate a differentiated combination strategy targeting complementary mechanisms of intestinal inflammation: OD-001 inhibits upstream RIPK2-mediated innate immune activation, while vedolizumab limits adaptive immune cell trafficking to the gut. By targeting innate immunity upstream of contemporary therapeutic targets, OD-001 is well positioned as a potential backbone for combination therapy. Building on previously reported Phase 2a proof-of-concept results for OD-001 monotherapy, the trial represents the first clinical evaluation of a combination approach targeting both innate and adaptive immunity in UC.<\/p>\n

The trial is expected to enroll up to 146 patients globally and evaluate OD-001 in combination with vedolizumab during a 12-week induction period, followed by maintenance with OD-001 monotherapy through Week 52. Odyssey expects to provide topline induction results from this trial in the second half of 2027.<\/p>\n

The poster presentation details are as follows:<\/p>\n

\n Title:<\/strong> A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Efficacy,\u00a0Safety, and Pharmacokinetics of OD-001, a RIPK2 Scaffolding Inhibitor, in Combination With\u00a0Vedolizumab in Moderate-to-Severe Ulcerative Colitis
Presenter:<\/strong> Bruce Sands, M.D., M.S., Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D.\u00a0Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai
Poster Number:<\/strong> 5698
Date and Time:<\/strong> Tuesday, October 13 from 10:30 a.m. \u2013 4:00 p.m. CDT
Room:<\/strong> Exhibit Halls A-D<\/p>\n

\n About Odyssey Therapeutics<\/strong>
\n
Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a\u00a0portfolio of internally discovered and developed medicines with its first program advancing through\u00a0multiple clinical milestones. Odyssey\u2019s portfolio leverages the scientific expertise of its team of\u00a0experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates\u00a0that the Company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.<\/p>\n

For more information, please visit www.odysseytx.com<\/a> and follow Odyssey on LinkedIn<\/a> or X<\/a>.<\/p>\n

\n Forward-looking Statements<\/strong>\n <\/p>\n

This press release includes certain disclosures that contain \u201cforward-looking statements,\u201d within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding Odyssey\u2019s design, initiation, conduct, and timing of its Phase 2a\u00a0clinical trial evaluating OD-001 in combination with vedolizumab; the expected enrollment and timing of topline induction results from the trial; the potential safety, efficacy, and therapeutic benefits of OD-001, alone or in combination with existing therapies, including its potential to provide deeper and more durable remission and overcome the therapeutic ceiling in ulcerative colitis and inflammatory bowel disease; the potential benefits of simultaneously targeting innate and adaptive immunity; the therapeutic potential of Odyssey\u2019s product candidates; and Odyssey\u2019s strategy, business plans, or financial performance.<\/p>\n

Forward-looking statements may be identified by words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cgoal,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould\u201d and variations of these words or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on Odyssey\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Factors that could cause actual results to differ materially include, but are not limited to, the unpredictable nature of preclinical and clinical development; reliance on third parties; competition; Odyssey\u2019s ability to leverage its team\u2019s scientific expertise and suite of tools to enable more informed drug research and development; intellectual\u00a0property; legal and regulatory developments; and the other risks and uncertainties described under\u00a0\u201cRisk Factors\u201d in the Company\u2019s most recently filed Quarterly Report on Form 10-Q and the Company\u2019s\u00a0other filings with the SEC. Forward-looking statements contained in this press release are made as of\u00a0this date, and Odyssey undertakes no duty to update such information except as required under\u00a0applicable law.<\/p>\n

\n Contact<\/strong>\n <\/p>\n

Benjamin Navon
Senior Director, Communications<\/p>\n

\n For investors\u00a0
<\/em>
\n investors@odysseytx.com<\/a>\n <\/p>\n

\n For media<\/em>
\n
\n media@odysseytx.com<\/a>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Topline induction results expected in the second half of 2027 BOSTON, Oct. 12, 2026 (GLOBE NEWSWIRE) — Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (\u201cOdyssey\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that it will present the design of a randomized, double-blind Phase 2a trial evaluating OD-001 in combination with vedolizumab in patients with moderate-to-severe ulcerative colitis (UC) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, taking place October 9-14, in Nashville, Tennessee. The trial is designed to evaluate a differentiated combination strategy targeting complementary mechanisms of intestinal inflammation: OD-001 inhibits upstream RIPK2-mediated innate … <\/p>\n

Continue reading “Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1009184","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOdyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Topline induction results expected in the second half of 2027 BOSTON, Oct. 12, 2026 (GLOBE NEWSWIRE) — Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (\u201cOdyssey\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that it will present the design of a randomized, double-blind Phase 2a trial evaluating OD-001 in combination with vedolizumab in patients with moderate-to-severe ulcerative colitis (UC) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, taking place October 9-14, in Nashville, Tennessee. The trial is designed to evaluate a differentiated combination strategy targeting complementary mechanisms of intestinal inflammation: OD-001 inhibits upstream RIPK2-mediated innate … Continue reading "Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-12T12:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzU2MSM3ODg5ODQ0IzIzMDk5NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026\",\"datePublished\":\"2026-10-12T12:04:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/\"},\"wordCount\":764,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzU2MSM3ODg5ODQ0IzIzMDk5NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/\",\"name\":\"Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzU2MSM3ODg5ODQ0IzIzMDk5NDc=\",\"datePublished\":\"2026-10-12T12:04:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzU2MSM3ODg5ODQ0IzIzMDk5NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzU2MSM3ODg5ODQ0IzIzMDk5NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/","og_locale":"en_US","og_type":"article","og_title":"Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026 - Market Newsdesk","og_description":"Topline induction results expected in the second half of 2027 BOSTON, Oct. 12, 2026 (GLOBE NEWSWIRE) — Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (\u201cOdyssey\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that it will present the design of a randomized, double-blind Phase 2a trial evaluating OD-001 in combination with vedolizumab in patients with moderate-to-severe ulcerative colitis (UC) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, taking place October 9-14, in Nashville, Tennessee. The trial is designed to evaluate a differentiated combination strategy targeting complementary mechanisms of intestinal inflammation: OD-001 inhibits upstream RIPK2-mediated innate … Continue reading \"Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-12T12:04:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzU2MSM3ODg5ODQ0IzIzMDk5NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026","datePublished":"2026-10-12T12:04:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/"},"wordCount":764,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzU2MSM3ODg5ODQ0IzIzMDk5NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/","name":"Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzU2MSM3ODg5ODQ0IzIzMDk5NDc=","datePublished":"2026-10-12T12:04:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzU2MSM3ODg5ODQ0IzIzMDk5NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzU2MSM3ODg5ODQ0IzIzMDk5NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1009184"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009184\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1009184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1009184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1009184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}